中国经济网北京12月12日讯博拓生物(688767.SH)昨日晚间发布实际控制人减持股份计划期间届满暨减 持股份结果公告。 公司于近日收到于秀萍出具的《关于减持计划期间届满暨减持股份结果的告知函》。2025年11月19日至 2025年12月2日，于秀萍通过集中竞价交易和大宗交易的方式合计减持公司股份4,479,900股，占公司当 前总股本的3.00%，减持价格区间为38.55元/股至41.77元/股，减持总金额175,077,100.70元。截至公告披 露日，于秀萍本次减持计划时间已届满。 博拓生物于2021年9月8日在上交所科创板上市，公开发行的新股数量为2666.67万股，发行价格为34.55 元/股，保荐机构(主承销商)为国泰君安证券股份有限公司(现名"国泰海通证券股份有限公司")，保荐代 表人为沈强、李小华。 博拓生物首次公开发行募集资金总额为9.21亿元，募集资金净额为8.29亿元，较原拟募资少6207.81万 元。博拓生物此前披露的招股书显示，公司原拟募资8.91亿元，拟分别用于年产4亿人份医疗器械(体外 诊断)产品扩建升级建设项目、体外诊断研发中心建设项目、体外诊断产品生产线智能化改造建设项 目 ...

Group 1 - The actual controller of Botao Bio (688767.SH), Yu Xiuping, reduced her shareholding by 3,636,600 shares, accounting for 2.44% of the company's total share capital, bringing her and her concerted parties' total shareholding down from 86,688,000 shares to 83,051,400 shares, which is a decrease from 58.05% to 55.61% of the total share capital [1] - On November 19, 2025, the weighted average price of Botao Bio's shares was 42.112 yuan, resulting in a total reduction amount of 153 million yuan for Yu Xiuping [1] Group 2 - The annual report for 2024 indicates that the actual controllers of Botao Bio are Chen Yinlong, Yu Xiuping, and Chen Yujie [2] - Botao Bio was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on September 8, 2021, with a public offering of 26.6667 million shares at a price of 34.55 yuan per share, raising a total of 921 million yuan [2] - The net amount raised from the initial public offering was 829 million yuan, which was 62.0781 million yuan less than originally planned [2] - The company initially intended to raise 891 million yuan for various projects, including the expansion of medical device production capacity and the establishment of a research and development center [2]

Core Viewpoint - The actual controller of Botao Bio (688767.SH), Yu Xiuping, announced a share reduction plan due to personal funding needs, intending to reduce up to 4,479,999 shares, which is no more than 3% of the total shares [1][2]. Summary by Relevant Sections Share Reduction Plan - Yu Xiuping plans to reduce shares through block trading or centralized bidding, with a maximum of 1,493,333 shares (1% of total shares) via centralized bidding and 2,986,666 shares (2% of total shares) via block trading [1][2]. - The reduction period is set for three months starting from 15 trading days after the announcement [1][2]. Shareholding Information - As of the announcement date, Yu Xiuping holds 24,953,600 shares, accounting for 16.71% of the total shares [2]. - The shares intended for reduction were acquired before the IPO and through rights distribution [2]. Financial Performance - Botao Bio's initial public offering raised a total of 921 million yuan, with a net amount of 829 million yuan after expenses, which were 91.96 million yuan [3]. - The net profits attributable to shareholders from 2021 to 2024 were 834 million yuan, 774 million yuan, 107 million yuan, and 170 million yuan, respectively [3].